Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia

PHASE2UnknownINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

December 31, 2016

Conditions
Hyperlipidemia
Interventions
DRUG

ARI-3037MO

Lipid lowering treatment Statins

Trial Locations (19)

14069

Rochester clinical Research,Inc, Rochester

23294

National Clinical Research inc, Richmond

23502

Health Research of Hampton Roads - Norfolk, Norfolk

30060

Sestron Clinical Research 833 Campbell Hill Street Suite 230, Marietta

32127

Progressive Medical Research, Port Orange

32216

Jacksonville Center for Clinical Research, Jacksonvile

33306

S&W Clinical Reserch, Fort Lauderdale

40213

Louisville Metabolic and Atherosclerosis Research Center, Louisville

44124

Ohio Clinical Research-Lyndhurst, Lyndhurst

45219

Sterling Research Group Ltd, Cincinnati

The Carl and Edyth Lindner Center for Reserch and education at the Christ Hospital, Cincinnati

45227

Metabolic and atherosclerosis Research center, Cincinnati

45245

IVA reserch, Cincinnati

45246

Sterling Research group, Ltd, Cincinnati

46260

Midwest Institute for Clinical Research, Indianapolis

73103

COR Clinical Research, Oklahoma City

91710

Catalina Reserch Institute, LLC, Chino

97404

Willamette Valley Clinical studies, Eugene

98057

Raninier Clinical Reserach, Renton

Sponsors
All Listed Sponsors
lead

Arisaph Pharmaceuticals Inc

INDUSTRY